NCT02715570 is a Phase 1 clinical trial of PC945 - single doses in Aspergillosis, sponsored by Pulmocide Ltd.

Who is sponsoring NCT02715570?

NCT02715570 is sponsored by Pulmocide Ltd.

What drugs are being tested in NCT02715570?

Interventions in NCT02715570: PC945 - single doses, Placebo - single doses, PC945 - repeat doses, Placebo - repeat doses.

What condition does NCT02715570 study?

NCT02715570 studies Aspergillosis.

Is NCT02715570 still recruiting?

NCT02715570 is currently completed. Last updated 1 May 2018.

Last reviewed 2018-05-01 · How we verify

NCT02715570

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945

Completed Phase 1 Last updated 1 May 2018

What this trial tests

Phase 1 trial testing PC945 - single doses in Aspergillosis in 29 participants. Completed in 27 April 2018.

Timeline

23 October 2017

Primary endpoint
27 April 2018

27 April 2018

Quick facts

Lead sponsor	Pulmocide Ltd
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	29
Start date	23 October 2017
Primary completion	27 April 2018
Estimated completion	27 April 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

PC945 - single doses — full drug profile →
Placebo - single doses — full drug profile →
PC945 - repeat doses — full drug profile →
Placebo - repeat doses — full drug profile →

Conditions studied

Aspergillosis — all drugs for Aspergillosis →

Sponsor

Pulmocide Ltd — full company profile →

Who can join

Adults 18 to 65, any sex, with Aspergillosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PC945 is a new medicine being developed for treatment of fungal lung diseases. The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent.
Cass L, Murray A, Davis A, Woodward K, et al · · 2021 · cited 50× · PMID 33340279 · DOI 10.1002/prp2.690
New Antifungal Agents with Azole Moieties.
Teixeira MM, Carvalho DT, Sousa E, Pinto E. · · 2022 · cited 44× · PMID 36422557 · DOI 10.3390/ph15111427
Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug <i>Candida auris</i>.
Billamboz M, Fatima Z, Hameed S, Jawhara S. · · 2021 · cited 39× · PMID 33803604 · DOI 10.3390/microorganisms9030634
Novel antifungal agents in clinical trials.
Jacobs SE, Zagaliotis P, Walsh TJ. · · 2021 · cited 34× · PMID 35136573 · DOI 10.12688/f1000research.28327.2
PC945, a Novel Inhaled Antifungal Agent, for the Treatment of Respiratory Fungal Infections.
Murray A, Cass L, Ito K, Pagani N, et al · · 2020 · cited 30× · PMID 33348852 · DOI 10.3390/jof6040373
Recent Antifungal Pipeline Developments against <i>Candida auris</i>: A Systematic Review.
Treviño-Rangel RJ, González GM, Montoya AM, Rojas OC, et al · · 2022 · cited 13× · PMID 36354911 · DOI 10.3390/jof8111144
The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.
Souza CM, Bezerra BT, Mellon DA, de Oliveira HC. · · 2025 · cited 11× · PMID 39897698 · DOI 10.1016/j.crmicr.2025.100341
Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma.
Calzetta L, Aiello M, Frizzelli A, Pistocchini E, et al · · 2022 · cited 7× · PMID 36140430 · DOI 10.3390/biomedicines10092330

Verify or expand the search:

Other recruiting trials for Aspergillosis

Currently open trials in the same condition.

NCT05045391 — Pulmonary Aspergillosis in Tuberculosis Patients · active not recruiting
NCT03828773 — PTX3-targeted Antifungal Prophylaxis · NA · recruiting

Other Pulmocide Ltd trials

Trials by the same sponsor.

NCT05238116 — Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory · Phase 3 · terminated
NCT05037851 — A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transp · Phase 2 · completed
NCT03905447 — The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients. · Phase 2 · terminated
NCT03870841 — The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis · Phase 2 · terminated
NCT03745196 — The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02715570 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pulmocide Ltd
Last refreshed: 1 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02715570.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing